Patents Assigned to Senju Pharmaceuticals Co., Ltd.
  • THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION
    Publication number: 20120288482
    Abstract: The present invention aims to provide a means for effectively and conveniently treating diseases wherein corneal endothelial cells poor in proliferative capacity in vivo are damaged. The present invention provides a therapeutic agent for corneal endothelial dysfunction containing (R)-(+)-N-(1H-pyrrolo [2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide <Y-39983> or a pharmacologically acceptable salt thereof (compound (Ia)) as active ingredient, an agent for promoting adhesion of corneal endothelial cells, containing compound (Ia), a culture medium for corneal endothelial cells, containing the agent for promoting adhesion, an implant for corneal endothelial keratoplasty, containing corneal endothelial cells, scaffold and compound (Ia), and a production method of a corneal endothelial preparation, including a step of cultivating corneal endothelial cells using the culture medium.
    Type: Application
    Filed: December 28, 2010
    Publication date: November 15, 2012
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION, SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Hiroaki Takahashi, Yuji Sakamoto, Tetsuo Kida, Takeshi Tarui
  • Aqueous intraocular penetration-promoting eye drop
    Patent number: 8299124
    Abstract: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 30, 2012
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Tomoko Fujimoto
  • PHARMACEUTICAL CONTAINING PPAR-DELTA AGONIST
    Publication number: 20120270910
    Abstract: Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoroethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.
    Type: Application
    Filed: May 20, 2008
    Publication date: October 25, 2012
    Applicants: SENJU PHARMACEUTICAL CO., LTD., NIPPON CHEMIPHAR CO., LTD.
    Inventors: Yoshikuni NAKAMURA, Ikuko HANANO, Jun INOUE
  • MEDICAL FLUID NOZZLE
    Publication number: 20120271252
    Abstract: Disclosed is a medical fluid nozzle which makes fluid drops less likely to remain at its tip portion after the medical fluid is dropped. The medical fluid nozzle 1 is a substantially cylindrical shape with a tip surface formed in a substantially planar shape. An annular ridge 10 is formed along the circumferential direction at the tip portion of the medical fluid nozzle 1. The ridge 10 is formed so as to be continuous with the tip surface of the medical fluid nozzle 1 and has an extended surface 11 formed with an increased diameter so as to be flush with the tip surface of the medical fluid nozzle 1.
    Type: Application
    Filed: September 24, 2010
    Publication date: October 25, 2012
    Applicant: Senju Pharmaceutical Co., Ltd.
    Inventor: Tadashi Otsuka
  • OPTHALMIC COMPOSITION CONTAINING XANTHAN GUM AND AMINO ACID
    Publication number: 20120269845
    Abstract: The present invention provides an ophthalmic composition containing xanthan gum, or xanthan gum and an amino acid, which has a superior corneal epithelial disorder-treating effect and a superior corneal epithelial cell-protecting effect.
    Type: Application
    Filed: April 26, 2010
    Publication date: October 25, 2012
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Koji DOI, Hiroshi AKI
  • PARTIAL PEPTIDE OF LACRITIN
    Publication number: 20120245102
    Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.
    Type: Application
    Filed: September 16, 2010
    Publication date: September 27, 2012
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Nakajima, Tomoko Nakajima, Mitsuyoshi Azuma
  • Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor
    Patent number: 8268794
    Abstract: Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1? expression and a substance specifically inhibiting HIF-2? expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1? and HIF-2?, or expression vectors thereof.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: September 18, 2012
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Takeshi Nakajima, Emi Nakajima, Mitsuyoshi Azuma
  • CORNEAL ENDOTHELIAL CELL PROLIFERATION PROMOTER
    Publication number: 20120190621
    Abstract: The present invention aims to provide a corneal endothelium cell proliferation accelerator and a therapeutic agent for a disease relating to corneal endothelium damage, which are administered into the anterior chamber. bFGF is released in a sustained manner by forming bFGF sustained-release gelatin hydrogel particles wherein bFGF is carried on gelatin hydrogel. Therefore, the proliferation of corneal endothelium cells can be accelerated persistently by administration of a preparation containing the bFGF sustained-release gelatin hydrogel particles into the anterior chamber, and diseases relating to corneal endothelium damage can be treated.
    Type: Application
    Filed: July 24, 2009
    Publication date: July 26, 2012
    Applicants: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Yasuhiko Tabata, Shigeru Kinoshita, Noriko Koizumi, Yuji Sakamoto, Naoki Okumura, Hiroaki Takahashi
  • LATANOPROST-CONTAINING AQUEOUS EYE DROPS AND METHOD FOR INHIBITING ADSORPTION OF LATANOPROST TO RESIN
    Publication number: 20120184552
    Abstract: The invention provides an aqueous eye drop containing latanoprost, a surfactant, and an aliphatic mono- or di-carboxylic acid having a carbon number of 3-10 or a salt thereof. In addition, the invention provides a method of suppressing adsorption of latanoprost to a resin in an aqueous solution, by adding a surfactant and an aliphatic mono- or di-carboxylic acid having a carbon number of 3-10 or a salt thereof.
    Type: Application
    Filed: September 17, 2010
    Publication date: July 19, 2012
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Tomoko Nakajima, Wakiko Asayama, Tetsuya Tajika
  • OIL-IN-WATER EMULSION COMPOSITION CONTAINING DIFLUPREDNATE AND TOBRAMYCIN
    Publication number: 20120135947
    Abstract: The present invention provides an oil-in-water emulsion composition for topical administration, containing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier. Moreover, it provides a method for stabilizing tobramycin, which includes mixing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier to form an oil-in-water emulsion. The present invention can provide an oil-in-water emulsion composition containing tobramycin, which can maintain tobramycin content stably even when a non-ionic surfactant is added.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 31, 2012
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION, SENJU PHARMACEUTICAL CO., LTD.
    Inventor: Yuko SHIKAMURA
  • Pharmaceutical comprising PPAR agonist
    Patent number: 8148389
    Abstract: An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPAR? or ? agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPAR? or ? agonist as an active ingredient.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: April 3, 2012
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
  • Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
    Patent number: 8129431
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: March 6, 2012
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Shuhei Fujita
  • RING-SHAPED DEVICE
    Publication number: 20120022473
    Abstract: The present invention aims to provide a ring-shaped device superior in the wearing comfort and intraocular stability while being worn on the eye. Provided is a ring-shaped device to be worn on the scleral surface, which is characterized in that it has an opening to expose the cornea and an intermediate portion between an inner edge portion and an outer edge portion has a maximum thickness.
    Type: Application
    Filed: December 25, 2009
    Publication date: January 26, 2012
    Applicants: SEED CO., LTD., SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Yuko Shikamura, Takao Sato, Toru Matsunaga, Yoshiko Yamazaki, Tsutomu Fukushima
  • Percutaneously absorptive ophthalmic preparation comprising olopatadine
    Patent number: 8101654
    Abstract: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: January 24, 2012
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Akiharu Isowaki, Tomoko Nakajima, Akira Ohtori
  • SOLID DISPERSION OF ALPHA-KETOAMIDE DERIVATIVES
    Publication number: 20120016020
    Abstract: A solid dispersion comprising ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester made amorphous in the presence of a water-soluble cellulosic polymer has improved storage stability. The solid dispersion also has improved solubility for an improved bioavailability.
    Type: Application
    Filed: July 13, 2011
    Publication date: January 19, 2012
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Andrew Xian CHEN, John FAN, Masazumi YAMAGUCHI
  • HYDROGEL CONTACT LENS FOR SUSTAINED DRUG RELEASE AND DRUG RELEASE METHOD USING HYDROGEL CONTACT LENS FOR SUSTAINED DRUG RELEASE
    Publication number: 20110306661
    Abstract: Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer.
    Type: Application
    Filed: January 15, 2010
    Publication date: December 15, 2011
    Applicants: SENJU PHARMACEUTICAL CO., LTD., SEED CO., LTD.
    Inventors: Takao Sato, Toru Matsunaga, Aya Ichinokawa, Osamu Sakai
  • PHARMACEUTICAL COMPOSITION CONTAINING PROSTAGLANDIN
    Publication number: 20110294880
    Abstract: An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F2? in a preparation containing prostaglandin F2?. The object was attained by formulating a prostaglandin F2? derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.
    Type: Application
    Filed: August 10, 2011
    Publication date: December 1, 2011
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Yusuke SAKAI, Akira Ohtori
  • PHARMACEUTICAL CONTAINING HIF-1 ALPHA AND HIF-2 ALPHA EXPRESSION INHIBITOR
    Publication number: 20110213008
    Abstract: Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1? expression and a substance specifically inhibiting HIF-2? expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1? and HIF-2?, or expression vectors thereof.
    Type: Application
    Filed: August 5, 2008
    Publication date: September 1, 2011
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Nakajima, Emi Nakajima, Mitsuyoshi Azuma
  • Agent for repairing corneal sensitivity containing amide compound
    Patent number: 7956072
    Abstract: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: June 7, 2011
    Assignees: Senju Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation
    Inventors: Yoshiko Takayama, Yoshikuni Nakamura, Jun Inoue, Mitsuyoshi Azuma
  • Ophthalmic composition containing xanthan gum and amino acid
    Patent number: 7939511
    Abstract: The present invention provides an ophthalmic composition containing xanthan gum, or xanthan gum and an amino acid, which has a superior corneal epithelial disorder-treating effect and a superior corneal epithelial cell-protecting effect.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: May 10, 2011
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Koji Doi, Hiroshi Aki